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Short Communication
Imatinib administration in two patients with liver metastases from
GIST and severe jaundice
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Imatinib is the only effective and approved systemic therapy for the treatment of patients with advanced gastrointestinal stromal
tumours (GISTs). Although metastases from GISTs most commonly involve the liver, yielding hyperbilirubinaemia, very few data on
imatinib administration in subjects with jaundice are available. We provide evidence that imatinib tolerability was not adversely
affected by jaundice in two patients with advanced GIST.
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Imatinib (Glivecs, formerly STI571), in the US imatinib mesylate
(Gleevect), the selective inhibitor of KIT BCR-ABL and PDGFR
tyrosine kinases, is the only effective and approved systemic
therapy for the treatment of patients with advanced gastrointest-
inal stromal tumours (GISTs) (van Oosterom et al, 2001; Demetri
et al, 2002).
Although metastases from GISTs most commonly involve the
liver, yielding hyperbilirubinaemia as an expected late complica-
tion in these patients, very few data on imatinib administration in
subjects with jaundice are available thus far (Bauer et al, 2002).
Imatinib is metabolised by demethylation in the liver to CGP74588,
which shows an in vitro activity similar to that of the parent drug
(Lyseng-Williamson and Jarvis, 2001). Moreover, most of an oral
dose of imatinib appears in the faeces: within 7 days, 81% of a
radiolabelled drug dose is eliminated by the hepatobiliary (68%)
and renal routes (13%), respectively (Lyseng-Williamson and
Jarvis, 2001). Most of this drug amount is represented by
metabolites with only 25% of the dose excreted as unmetabolised
imatinib (Bauer et al, 2002). For these reasons, drug elimination
and treatment tolerability might be adversely affected by hepatic
dysfunction.
However, we describe the absence of significant toxicity of
imatinib administered to two patients with advanced GIST and
severe jaundice.
MATERIALS AND METHODS
In all, 22 patients with histologically documented diagnosis of
metastatic GIST and immunohistochemical documentation of c-kit
(CD117) expression by tumour were included in a clinical trial
approved by our Ethical Committee and received Glivec.
We report on two patients who received a full-dose adminis-
tration of Imatinib for extended periods of time despite severe
jaundice.
RESULTS
Case 1
The first patient was a 67-year-old male treated with imatinib
800mg (400mg b.i.d.) p.o. for synchronous omental and liver
metastases from gastric GIST. More than 10 liver metastases were
observed at the time of diagnosis, with the longest diameter up to
50mm. The patient had no relevant hepatobiliary medical record;
red cell transfusions were given for WHO G4 anaemia (5.1 g dl1)
before starting imatinib administration. The first three treatment
weeks were uneventful; then imatinib administration was discon-
tinued because of G2 rash and oedema. During the next 2 weeks
after treatment discontinuation, the patient suffered from a G3
elevation of transaminases and increase in both alkaline phospha-
tase and serum bilirubin (4.1mg dl1, conjugated 3.8mg dl1). A
liver ultrasound and an abdominal CT scan showed a tumour
stabilisation, without remarkable anatomic changes, such as biliary
duct compression; HAV, HBV and HCV markers were negative.
The pathogenesis of the cholestasis remained unclear, even if a
drug-related hepatotoxicity or a toxicity related to the previous
red-cell transfusions were hypothesised. The cholestasis worsened,
with alkaline phosphatase up to 4118 IU l1 and serum bilirubin up
to 12.2mg dl1 (refer to the graphic). At 6 weeks after treatment
discontinuation, despite a persistent jaundice (total serum
bilirubin 10.8mg dl1, conjugated 8.1mg dl1) and without evi-
dence of disease progression, the treatment with imatinib was
resumed at the reduced dose of 400mg p.o. day1; dexamethasone
8mg daily was also initiated.
After 6 weeks of imatinib treatment, jaundice resolved: in this
period of time, only G2 oedema occurred, not requiring treatment
discontinuation nor dose reduction. Stable disease and subsequentReceived 3 March 2003; revised 16 May 2003; accepted 18 July 2003
*Correspondence: Dr T De Pas; E-mail: tommaso.de-pas@ieo.it
British Journal of Cancer (2003) 89, 1403 – 1404
& 2003 Cancer Research UK All rights reserved 0007 – 0920/03 $25.00
www.bjcancer.com
C
li
n
ic
a
l
disease progression were confirmed by CT scan 2 and 5 months
after treatment restarting, respectively (refer to the graphic).
Case 2
The second patient was a 42-year-old female treated with imatinib
400mg p.o. day1 for synchronous liver metastases (more than 10,
up to 120mm of the longest diameter) from a retroperitoneal GIST
refractory to ifosfamide plus doxorubicin chemotherapy. The
patient had no relevant hepatobiliary medical record. The first 10
weeks of treatment were uneventful; then treatment was discon-
tinued because of G3 elevation of transaminases and G2 increase in
alkaline phosphatase, followed, a few days later, by a conjugated
hyperbilirubinaemia (6.4mg dl1) (refer to the graphic). An
abdominal CT scan performed 8 weeks after treatment start
showed a minor response (less than 30% according to RECIST
criteria), without relevant anatomic changes, such as biliary duct
compression. At 20 days after treatment discontinuation, serum
bilirubin increased up to 11.2mg dl1 and a liver ultrasound and
CT scan showed disease progression (more than 20% of the longest
diameter in most liver metastases) with no biliary duct compres-
sion. According to this observation, a disease-progression-related
cholestasis was hypothesised. According to an informed patient’s
preference, administration of imatinib 400mg p.o. day1 was
resumed and delivered in combination with dexamethasone 8mg
daily for 11 weeks, despite a persistent jaundice (serum bilirubin
decreased to 3mg dl1 after 3 weeks, then increased up to
9mg dl1). During this period of treatment, no G2-4 imatinib-
related toxicity was observed, and treatment was delivered without
interruptions or dose reductions.
Afterwards (week 25), because of the worsening jaundice
(serum bilirubin 9mg dl1), drug administration was discontinued
again and the dose of dexamethasone increased up to 12mg
p.o. day1.
At 2 weeks after treatment discontinuation, a CT scan showed a
disease progression in the liver (more than 30% according to
RECIST criteria), with no biliary duct compression. Then,
according to the patient’s preference, the treatment was restarted,
increasing the dose of imatinib to 800mg (400mg b.i.d.) p.o.,
despite a severe hyperbilirubinaemia (13.9mg dl1). At 11 weeks
after the dose of imatinib was increased, a CT scan showed disease
stabilisation; furthermore, an improvement in both jaundice
(serum bilirubin 2.5mg dl1) and disease-related symptoms was
observed (refer to the graphic). The patient did not suffer from
drug-related side effects, although imatinib was given in the
presence of persistent hyperbilirubinaemia (Figure 1).
DISCUSSION
With this report, we provide evidence that imatinib tolerability was
not adversely affected by jaundice, in two patients with advanced
GIST, despite full-dose administration of the drug for extended
periods of time. This information should be considered with
caution, since only two patients were examined and the lack of
pharmacokinetic analysis and liver tissue analyses did not provide
a clear interpretation of these data. Theoretically, elimination of
imatinib is expected to be impaired to some degree in patients with
hepatobiliary dysfunction, and a pharmacokinetic study of
imatinib in patients with hepatic impairment is currently under-
way.
Imatinib has a very high rate of clinical benefit in patients with
c-KIT-positive GIST and, in the absence of other systemic
treatment options, it is the only chance of cure in this subset of
patients. According to this limited experience and until more
information is available, Glivec administration in patients with
advanced GIST and jaundice should be cautiously considered.
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